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Systemic amyloid light chain (AL) amyloidosis is rare complication of 
Waldenström’s Macroglobulinaemia (WM) and 6% of patients with AL 
amyloidosis have WM or an IgM monoclonal protein at presentation.
1
 Symptoms 
of peripheral neuropathy (PN) are present in about 20% of patients with WM at 
diagnosis, and up to 50% are affected at some time in the course of their 
disease.
1
 The neuropathy is most frequently a distal chronic symmetrical, 
predominantly sensory polyneuropathy related to the presence of pathogenic 
monoclonal anti-myelin associated glycoprotein (MAG) antibodies.
2
 Where 
atypical features exist, such as predominant motor involvement, patchy 
localisation, rapid progression or autonomic dysfunction, alternative causes 
including amyloidosis, cryoglobulinaemic vasculitis and direct nerve infiltration 
must be considered.
3
 Diagnosis of isolated neuropathic amyloidosis is 
challenging particularly as tissue biopsy other than the affected nerves may be 
negative for amyloid deposits.  Patchy amyloid deposits in nerves or nerve plexii 




Here, we report the case of a 51-year-old male with WM, who presented eight 
years following the initial diagnosis with progressive sensory disturbance in his 
distal upper limbs and bilateral wasting and weakness of the small muscles of 
the left hand.  At presentation, he had weight loss, night sweats, monoclonal IgM 
of 55g/L and bone marrow consistent with lymphoplasmacytic lymphoma.  He 
obtained a very good partial response to six cycles of R-CHOP, followed by 
autologous stem cell transplant conditioned by BCNU, Etoposide, Cytarabine and 
Melphalan (BEAM).  He had remained well until shortly before his neurological 
presentation, but was under closer review due to a rising paraprotein. Clinical 
examination was consistent with a patchy, multifocal bi-brachial plexopathy.  
Nerve conduction studies confirmed this with a patchy sensorimotor neuropathy 
with non-uniform conduction slowing, likely to be predominantly in the distal 
plexus and below.   
 
CT scan showed mild further size increase of long-standing, slowly progressing 
lymphadenopathy above and below the diaphragm. MRI scans of the brain, 
spinal cord and brachial plexi did not reveal a cause of the patient’s symptoms. 
FDG PET-CT showed isolated high uptake in the mediastinal nodes (SUVmax of 
up to 12.1) but non-specific modest uptake in the more assessable peripheral 
nodes (nodal uptake similar to, or less than, liver background activity of SUVmax 
3.4, but higher than mediastinal blood pool of SUVmax 1.8) (Figure 1&2).  There 
was no specific hypermetabolism at the brachial plexus or peripheral nerves, nor 
any extranodal abnormality.  His CSF showed normal protein of 0.42 g/L, no cells 
but a raised CSF IgM commensurate with the serum. The M-protein was rising 
(24.6 g/L) but blood tests for anti-MAG antibodies and cryoglobulin were 
negative. Overall the patchy bibrachial neuropathy in the context of the known 
WM progressing despite treatment gave a strong clinical suspicion of 
amyloidosis.  There was no evidence of systemic amyloidosis on investigations 
with normal cardiac biomarkers, no proteinuria, normal echocardiogram, no 
evidence of amyloid deposition on a bone marrow biopsy, and a normal 
123
I 
labelled serum amyloid P component and 
99m
Tc DPD scintigraphy.   
 
 3
Owing to a gradual but steady deterioration in his neuropathy, he received a trial 
of high dose methylprednisolone, which had no effect. Three months later, repeat 
MRI showed some thickening of the ulnar nerve suggestive of an infiltrative 




F]florbetaben PET-CT scan was performed in an attempt to identify neural 
amyloid deposition.  This was performed within two months of the FDG PET-CT.  
300MBq of [
18
F]florbetaben was injected into a peripheral vein, with scan 
acquisition starting 90 minutes post injection. No discrete peripheral neural 
uptake was observed.  However, this unexpectedly showed clearly abnormal, 
marked increased focal uptake throughout the known lymphadenopathy above 
and below the diaphragm, despite there being no measurable further increase in 
nodal disease burden by CT criteria since the FDG PET-CT (range of nodal 
[
18
F]florbetaben uptake SUVmax 7.4-18.6; by comparison, mediastinal blood 
pool SUVmax was 1.5 & liver parenchymal SUVmax was 8.5).(Figure 1&2) This 
provided justification for relatively less-invasive, targeted, percutaneous biopsy 
of a modestly enlarged axillary node.  Histology showed that the lymph node was 
effaced by lymphoplasmacytic infiltrate and there was pathological thickening of 
the blood vessels walls. Amyloid deposition was confirmed by demonstration of 
typical Congo red staining with characteristic birefringence under cross-
polarised light (see figure 3). Confirmation of the presence of amyloid in this WM 
patient contributed to the justification for the subsequent recommencement of 
specific treatment and the need to aim for a deeper response than might 




F]florbetaben is a novel PET tracer, which has been shown to accurately 
detect beta-amyloid plaques in the brains of patients to aid diagnosis of 
Alzheimer’s Disease. 
5
 There have been a few reports and in vitro results 
suggesting that similar thioflavin like, 
18
F-labelled PET tracers may have utility in 
identifying amyloid deposition in tissues other than the brain. In vitro binding of 
[
18
F]florbetapir has been demonstrated in autopsy myocardial specimens. 
Interestingly, although [
18
F]florbetapir binds to both AL amyloid and 
transthyretin (ATTR) amyloid, binding was significantly higher to AL amyloid.
6
 
One previous case report demonstrated the potential ability of [
18
F]florbetapir  
to detect peripheral nerves involvement, with a small case series suggesting 
utility in assessing amyloid deposition in the heart. 
7,8
 Another isolated report 
with [
18
F]florbetaben had shown its potential utility  in systemic amyloidosis 
staging. This latter report contrasted the abnormal increased uptake in a patient 
with cardiac and renal amyloidsis, with the normal  [
18
F]florbetaben distribution 




F]florbetapir shows uptake in a 
number of tissues outside of the heart – in a recent of series of 17 patients 
studied at the UK National amyloidosis centre, all 17 showed extra-cardiac 
uptake at more than one site (Wagner and Wechalekar – personal 
communication – manuscript under review).  
 
The results of the [
18
F]florbetaben PET-CT scan in this case were remarkable and 
surprising, given the exhaustive investigations that had taken place previous to 
this.  It demonstrates the utility of [
18
F]florbetaben PET in identifying lymphoid 
amyloid uptake - an anatomical site that can be silent on conventional workup. 
 4
The identification of amyloid in this case justified commencing systemic therapy 
with an approach that will be tailored to account for the confirmed amyloid 
diagnosis. Our experience along with other isolated reports suggest potential 
added value of these novel PET tracers in the diagnostic work up of haematology 
patients at risk of developing amyloidosis.   
 
Trials are currently on-going to assess the utility of 
18
F-labelled tracers for 
assessing cardiac amyloid and peripheral nerve in general cohorts.  
Nevertheless, systematic evaluation of its impact in guiding management of 
haematological patients, for which confirmation of the presence of amyloidosis is 
highly relevant, would be needed.   
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Coronal image Sections. From left to right: a) Maximum intensity projection 
(MIP) of the whole body [
18
F]florbetaben PET-CT; b) Coronal fused PET-CT view 
of [
18
F]florbetaben PET; c) MIP of the whole body FDG PET-CT; d) Coronal fused 
PET-CT view of the FDG PET-CT.   These overview images show marked focal 
increased [
18
F]florbetaben uptake in numerous size prominent lymph nodes 
above and below the diaphragm.  These mostly only show non-specific modest 






Axial image sections. From left to right: axial CT, PET and fused images of 
[
18
F]florbetaben (top row) & FDG (bottom row) PET-CT.  These are 
representative images taken at the axial level of axilla.  Most avid and largest left 
axillary node at this level measured 1.4x2.3cm on both studies, with SUVmax of 
18.6 on [
18
F]florbetaben & 2.7 on FDG PET-CT.  Mediastinal nodes have SUVmax 
of 15.6 on [
18
F]florbetaben & 12.1 on FDG PET-CT respectively. Bilateral pleural 
effusion is also evident. 
 
Figure 3  
 
Histology sections. (A) H&E - The lymph node is effaced by a lymphoid infiltrate 
with amyloid deposition and thickening of the blood vessel walls; 
Immunohistochemistry demonstrates CD20 staining (B) and the plasmacytic 
CD138+ component (C). Amyloid stains positive with Congo red with apple green 
birefringence under polarised light (D)  
  
 
 



